The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
Open accessAbstract
Drug repositioning refers to the discovery of alternative uses for drugs--uses that are different from that for which the drugs were originally intended. One challenge in this effort lies in choosing the indication for which a drug of interest could be prospectively tested. We systematically evaluated a drug treatment-based view of diseases in order to address this challenge. Suggestions for novel drug uses were generated using a "guilt by association" approach. When compared with a control group of drug uses, the suggested novel drug uses generated by this approach were significantly enriched with respect to previous and ongoing clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
New drug development in the United States from 1963 to 1999
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115132 · Cited by 251
Exploring the Geometry of Treatment Networks
Salanti, G., Kavvoura, F. K., & Ioannidis, J. P. A. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-7-200804010-00011 · Cited by 231
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S. V., Goldstein, M. J., Shirer, A. E., Sharpe, O., Chen, J., Mitchell, D. J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-048033 · Cited by 65
Fromigué, O., Hamidouche, Z., & Marie, P. J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136127 · Cited by 41
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
“…drug repurposing including drug-drug similarity ( Gottlieb et al., 2011 ; Li and Lu, 2012 ), disease-disease similarity ( Gottlieb et al., 2011 ; Chiang and Butte, 2009 ), transcriptional signatures ( Lamb, 2007 ; Qu and Rajpal, 2012 ; Cheng et al., 2014 ; Lamb et al., 2006 ; Iorio et al., 2013…”
BackgroundExploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
Self-citationDrug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm
Luo, H., Wang, J., Li, M., Luo, J., Peng, X., Wu, F.-X., & Pan, Y. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw228 · Cited by 477
Machine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
Computational Drug Repositioning: From Data to Therapeutics
Hurle, M. R., Yang, L., Xie, Q., Rajpal, D. K., Sanseau, P., & Agarwal, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.1 · Cited by 373
Drug repositioning by integrating target information through a heterogeneous network model
Wang, W., Yang, S., Zhang, X., & Li, J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu403 · Cited by 335
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288
Systematic Drug Repositioning Based on Clinical Side-Effects
Yang, L., & Agarwal, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028025 · Cited by 266
Toward better drug discovery with knowledge graph
Zeng, X., Tu, X., Liu, Y., Fu, X., & Su, Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.09.003 · Cited by 229
Luo, H., Chen, J., Shi, L., Mikailov, M., Zhu, H., Wang, K., He, L., & Yang, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr299 · Cited by 206
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
“Moreover, another level of complexity can be added by combining, for example, epidemiologic information obtained in-house and/or from publicly available literature databases with in vitro experimental molecule screenings with the aim to identify novel indications, as in the case of digoxin and prostate cancer (67, 68).”
BackgroundA drug repositioning algorithm based on a deep autoencoder and adaptive fusion
Chen, P., Bao, T., Yu, X., & Liu, Z. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04406-y · Cited by 8
Metadata
- Authors
- Chiang, A. P., & Butte, A. J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-07-01
- Volume
- 86
- Issue
- 5
- Pages
- 507-510
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1994658365
- Cited by
- 268
- References
- 11
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.